NCT03193645View on ClinicalTrials.gov

Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix

CompletedOBSERVATIONAL
Enrollment

150

Participants

Timeline

Start Date

June 27, 2017

Primary Completion Date

June 30, 2018

Study Completion Date

January 31, 2019

Conditions
Prostate Cancer
Interventions
DRUG

Degarelix

Injection

Trial Locations (1)

Unknown

Hopital de la Source (there may be multiple sites in this country), Orléans

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT03193645 - Observational Prospective Study Describing the Global Patient Care and Follow-up of Prostate Cancer Patients Treated With Degarelix | Biotech Hunter | Biotech Hunter